A5060604035- Cervical Cancer and HPV Research
- Hepatitis B Virus Studies
- Immunotherapy and Immune Responses
- HIV Research and Treatment
- SARS-CoV-2 and COVID-19 Research
- Immune Cell Function and Interaction
- Animal Virus Infections Studies
- Inflammatory Biomarkers in Disease Prognosis
- Adipokines, Inflammation, and Metabolic Diseases
- SARS-CoV-2 detection and testing
- Immune Response and Inflammation
- Virus-based gene therapy research
- Herpesvirus Infections and Treatments
- COVID-19 Clinical Research Studies
- Genital Health and Disease
- Molecular Biology Techniques and Applications
- Reproductive System and Pregnancy
- T-cell and B-cell Immunology
- Cytokine Signaling Pathways and Interactions
- RNA Interference and Gene Delivery
- Endometrial and Cervical Cancer Treatments
- Genetic factors in colorectal cancer
- Monoclonal and Polyclonal Antibodies Research
- Poxvirus research and outbreaks
- Neuropeptides and Animal Physiology
Leidos (United States)
2016-2025
Frederick National Laboratory for Cancer Research
2016-2025
National Cancer Institute
2013-2024
Leidos Biomedical Research Inc. (United States)
2015-2024
University of Minho
2020-2024
Science Applications International Corporation (United States)
2005-2023
Mwanza Intervention Trials Unit
2023
National Institute for Medical Research
2023
London School of Hygiene & Tropical Medicine
2023
Hull York Medical School
2023
Peripheral blood mononuclear cells (PBMCs) from many asymptomatic individuals infected with human immunodeficiency virus-type 1 (HIV) are unresponsive as measured by in vitro T cell proliferation and interleukin-2 (IL-2) production to influenza virus synthetic peptides of HIV envelope (Env). Strong virus- Env-stimulated IL-2 responses were restored when cultures stimulated the presence IL-12. Interferon-gamma PBMCs seropositive (HIV+) patients was also Furthermore, antigen-specific HIV-...
A comprehensive characterization of the effects cigarette smoke on systemic soluble immune/inflammatory markers may provide insight into mechanisms through which smoking causes disease. Levels 78 inflammation, immune, and metabolic were measured using multiplex immune assays in 1819 Prostate, Lung, Colorectal Ovarian Cancer Screening Trial (PLCO) participants aged 55 to 74 years from three existing nested case-control studies. These data made representative entire PLCO screening arm...
Abstract The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine efficacy against 12-month persistent infection was similarly high among women who received one, two, or the recommended three doses of bivalent L1 virus-like particle (VLP) vaccine. Live-attenuated viral vaccines, but not simple-subunit usually induce durable lifelong antibody responses after a single dose. It is unclear whether noninfectious VLP vaccines behave more like live-virus in this regard. To explore...
Despite growing recognition of an etiologic role for inflammation in lung carcinogenesis, few prospective epidemiologic studies have comprehensively investigated the association circulating markers with cancer. We conducted a nested case–control study (n = 526 cancer patients and n 592 control subjects) within Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial. Control subjects were matched to case on age, sex, follow-up time (median 2.9 years), randomization year, smoking...
Abstract Background The authors investigated the durability of vaccine efficacy (VE) against human papillomavirus (HPV)16 or 18 infections and antibody response among nonrandomly assigned women who received a single dose bivalent HPV compared with multiple doses unvaccinated women. Methods were between HPV16 18-vaccinated aged to 25 years one (N = 112), two 62), three 1365) doses, age- geography-matched 1783) in long-term follow-up Costa Rica Vaccine Trial. Cervical measured at study visits,...
BackgroundAn estimated 15% of girls aged 9–14 years worldwide have been vaccinated against human papillomavirus (HPV) with the recommended two-dose or three-dose schedules. A one-dose HPV vaccine schedule would be simpler and cheaper to deliver. We report immunogenicity safety results different doses two vaccines in Tanzanian girls.MethodsIn this open-label, randomised, phase 3, non-inferiority trial, we enrolled healthy schoolgirls from Government schools Mwanza, Tanzania. Eligible...
BackgroundThe first randomised controlled trial of single-dose human papillomavirus (HPV) vaccine efficacy, the Kenya HPV-vaccine efficacy (KEN SHE) trial, showed greater than 97% against persistent HPV16 and HPV18 infection at 36 months among women in Kenya. We compared antibody responses after one dose HPV Dose Reduction Immunobridging Safety Study (DoRIS), single- regimen girls aged 9–14 years, target age range for vaccination, with those same KEN SHE.MethodsIn DoRIS 930 years Tanzania...
Identification of the components protective immunity are crucial for development effective prophylactic and therapeutic vaccine strategies. Analysis HIV-specific responses in exposed but uninfected individuals might thus provide a unique resource to elucidate correlates HIV. In present study we analyzed cytotoxic helper T lymphocyte health care workers (HCW) body fluids from HIV-positive individuals. HCW blood HIV-negative as well healthy donors served controls. Cytotoxic (CTL) HIV envelope...
AbstractTo monitor immune status during clinical trials and after vaccine registration, several assays have been developed to measure type-specific human papillomavirus (HPV) serum antibody levels. These include neutralization assays, single epitope-based inhibition immunoassays, direct enzyme-linked immunosorbent (ELISAs). Neutralization based on multiple epitopes independent of material are considered the ‘gold standard’ for unbiased assessment protective potential...
The Costa Rica Vaccine Trial (CVT), a phase III randomized clinical trial, provided the initial data that one dose of HPV vaccine could provide durable protection against infection. Although study design was to administer all participants three doses or control vaccine, 20% women did not receive three-dose regimens, mostly due involuntary reasons unrelated vaccination. In 2011, we reported single bivalent be as efficacious using endpoint persistent infection accumulated over first four years...
When administered as standard three-dose schedules, the licensed HPV prophylactic vaccines have demonstrated extraordinary immunogenicity and efficacy. We summarize of these most commonly used serology assays, with a focus on key considerations for one-dose vaccine schedules. Although immune correlates protection against infection are not entirely clear, both preclinical clinical evidence point to neutralizing antibodies principal mechanism protection. Thus, assessments in trials focused...
Human papillomavirus (HPV) vaccines are given as a two-dose schedule in children aged 9-14 years, or three doses older individuals. We compared antibody responses after one dose of HPV vaccine the Dose Reduction Immunobridging and Safety Study (DoRIS), randomised trial different schedules Tanzania, to those from two observational trials that found high efficacy up 11 years against HPV16 HPV18 (Costa Rica Vaccine Trial [CVT] Institutional Agency for Research on Cancer [IARC] India trial).
World Health Organization human papillomavirus (HPV) vaccination recommendations include a single- or two-dose schedule in individuals 9–20 years old and advice for generating data on single-dose efficacy immunobridging. The ongoing Phase 3 trial of Innovax's bivalent (types 16 18) HPV vaccine (Cecolin®) assesses low- middle-income countries alternative dosing schedules generates following one dose girls 9–14 old. Interim the 6-month groups are presented. In Bangladesh Ghana, 1,025 were...
Human papillomavirus (HPV) vaccines have been available for nearly 20 years. However, the overall coverage of girls aged 15 years and younger is low, especially in low-resource settings, where burden cervical cancer highest. Increasing access facilitating implementation HPV vaccination will contribute to elimination efforts. To generate data different dosing regimens we aimed evaluate safety immunogenicity various schedules an Escherichia coli-expressed bivalent vaccine (2vHPV) compared with...
The causal association between papillomavirus (HPV) infection and cervical cancer has been demonstrated; the development of a prophylactic vaccine to protect against HPV may therefore reduce incidence this worldwide. Noninfectious HPV-like particles (VLPs), composed L1 major capsid protein, are current candidate vaccines for prevention neoplasia. Although neutralizing antibodies have pivotal role in initial infection, cellular immune responses antigens an important viral clearance. A phase...
Abstract The development of cervical cancer and its precursors are linked to persistent infection with oncogenic types human papillomavirus (HPV). Host immune responses seem be determinants risk for this disease. However, little is known about the immunologic HPV persistence. Here, we examined association between lymphoproliferative antigens/mitogens in women older than 45 years. Women included study were participants a 10,000-woman population-based cohort neoplasia Costa Rica. years DNA...
Abstract Background: mRNA expression signatures are frequently used as surrogate measures of cellular function and pathway changes. Few studies have directly compared results obtained using gene multiplex protein assays for corresponding products. Methods: We data available from a clinical trial human papillomavirus-16 vaccine that tracked cytokine/chemokine production by peripheral blood mononuclear cells stimulated in culture with various antigens to evaluate the degree which levels...
Abstract Background: Chronic inflammation is etiologically related to several cancers. We evaluated the performance [ability detect concentrations above assay's lower limit of detection, coefficients variation (CV), and intraclass correlation (ICC)] 116 inflammation, immune, metabolic markers across two Luminex bead–based commercial kits three specimen types. Methods: From 100 cancer-free participants in Prostate, Lung, Colorectal, Ovarian Cancer Trial, serum, heparin plasma, EDTA plasma...